^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    senl_BCMA

    i
    Associations
    News

    Trials

    Company:
    SenlangBio
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies (NCT05618041)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    12/06/2022
    Initiation :
    09/07/2022
    Primary completion :
    09/06/2024
    Completion :
    12/06/2024
    CD8 • IL6 • CD4 • IL10
    |
    cyclophosphamide • senl_BCMA
    Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04447573)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/29/2020
    Initiation :
    06/30/2020
    Primary completion :
    08/30/2022
    Completion :
    12/30/2022
    IFNG • IL6 • TNFA • IL10
    |
    cyclophosphamide • SENL-B19 • senl_BCMA